CHMP recommend market authorisation for filgotionib (Jyseleca)

This oral reversible inhibitor of the Janus kinase (JAK) family is intended to be licensed for moderate to severe rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease DMARDs.

European Medicines Agency